InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Speak at 2025 Milken Institute Future of Health Summit
November 3, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering transformative mental health treatments, today announced that its Chief Medical Officer, Amir Inamdar, will participate in a panel discussion at the 2025 Milken Institute Future of […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Closes US$175 Million Registered Direct Offering Led by Top Healthcare Investors
October 31, 2025
This article has been disseminated on behalf of Cybin Inc. and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering next-generation mental health therapeutics, announced the closing of its previously disclosed registered direct offering for gross proceeds of approximately US$175 million. The financing included 22,277,750 common […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces US$175M Registered Direct Offering With Warrants Priced at US$6.51
October 28, 2025
This article has been disseminated on behalf of Cybin and may include paid advertising. Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced a registered direct offering of 22,277,750 common shares and, in lieu of shares for certain investors, pre-funded common share purchase warrants at US$6.51 per share or pre-funded warrant for aggregate gross proceeds of US$175,009,911.45; […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Highlights Clinical and Regulatory Milestones, Prepares for Upcoming Catalysts
September 24, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company, outlined key advancements across its proprietary drug discovery platforms and upcoming milestones. The Company emphasized its intellectual property portfolio extending through 2041 and its scalable manufacturing partnership with Thermo Fisher Scientific for the CYB003 program. Key near- and mid-term catalysts include topline data […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives to Present at TD Cowen Neuropsychiatry & Epilepsy Summit
September 11, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on Sept. 17, 2025, at 9:20 a.m. ET. To […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes Enrollment in Phase 2 CYB004 Study for Generalized Anxiety Disorder
September 8, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced it has completed enrollment in its Phase 2 study of CYB004, a proprietary deuterated dimethyltryptamine (DMT) program for the treatment of Generalized Anxiety Disorder (GAD). Topline data are expected in the first quarter of 2026. Interim CEO Eric So […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at H.C. Wainwright Global Investment Conference
September 4, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8, 2025, at 11:00 a.m. ET. To view the full press release, visit https://ibn.fm/jkHN9 About Cybin […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Participate in Cantor Global Healthcare Conference
September 3, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation treatment options for mental healthcare, announced that Chief Medical Officer Amir Inamdar will take part in a fireside chat at the Cantor Global Healthcare Conference, scheduled for Sept. 3–5, 2025. The session will be webcast live on Friday, Sept. 5, at 10:20 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Appoints Co-Founder Eric So as Interim CEO
September 2, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) announced that, effective Sept. 2, 2025, Doug Drysdale stepped down as Chief Executive Officer and was succeeded on an interim basis by Co-Founder and President Eric So. The Board of Directors has formed a committee to conduct a search for a new CEO to lead the Company through […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Australian Approval to Begin EMBRACE Phase 3 Study of CYB003
August 26, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company focused on next-generation treatment options, announced approval in Australia to conduct the EMBRACE study, the second pivotal trial in PARADIGM, its Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. Approval was granted through the Clinical Trial Notification scheme, with clearance from […]
SEGG Media Corporation (NASDAQ: SEGG): Multi-Vertical Strategy Powers Global Sports Entertainment Expansion
August 21, 2025
The sports entertainment industry is experiencing a fundamental shift that extends far beyond traditional broadcasting and venue management. As digital engagement becomes increasingly sophisticated, companies are discovering that success requires more than single-platform dominance; it demands integrated ecosystems that connect physical experiences with digital communities across multiple touchpoints. This convergence creates both opportunity and complexity. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Annual Meeting Voting Results
August 19, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental healthcare treatments, announced the results of its annual meeting of shareholders held Aug. 18, 2025. A total of 90 shareholders were represented in person or by proxy, holding 11,264,212 common shares, which accounted for 48.92% of the Company’s issued and outstanding […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q1 2025 Results, Advances Phase 3 Depression Program and Nears Completion of Phase 2 Anxiety Study
August 14, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, reported unaudited Q1 2025 results and key program updates. The company gained European Clinical Trial Application and UK MHRA approval to begin EMBRACE, expanding its multinational Phase 3 PARADIGM program of CYB003 for adjunctive treatment of major depressive disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives EU Approval to Launch EMBRACE Phase 3 MDD Study
August 7, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced European approval to initiate its EMBRACE(TM) Phase 3 study in Ireland, Poland, and Greece. EMBRACE is part of the Company’s PARADIGM(R) program evaluating CYB003, a proprietary deuterated psilocin analog granted Breakthrough Therapy Designation by the FDA for Major Depressive Disorder. The study will […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Present at Canaccord Genuity Growth Conference
August 6, 2025
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, announced that CEO Doug Drysdale will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The live webcast will take place at 2:30 p.m. ET, with an archived version […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Receives MHRA Approval to Launch Second Phase 3 Trial for CYB003 in Depression
July 17, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, announced UK MHRA approval to initiate EMBRACE, the second pivotal trial in its Phase 3 PARADIGM program evaluating CYB003, a proprietary deuterated psilocin analog for Major Depressive Disorder (MDD). CYB003 previously received Breakthrough Therapy Designation from the U.S. FDA. EMBRACE will enroll 330 patients with […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days
July 7, 2025
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced it expects data from two key preclinical studies of its lead candidate SPC-15 within 30 to 90 days. SPC-15 is an intranasal prophylactic designed to boost stress resilience and prevent Post-Traumatic Stress Disorder (PTSD). The ongoing studies include IND-enabling GLP-compliant toxicology and toxicokinetic testing, as well […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures $50 Million in Convertible Debenture Financing from High Trail
July 2, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company developing next-generation psychedelic-based treatments, has closed a private placement with High Trail Special Situations LLC for $50 million in unsecured convertible debentures, as part of an agreement that allows for up to $500 million in total funding. The financing will support the advancement of Cybin’s […]
ONAR Holding Corp. (ONAR): Why Smart Agencies Are Choosing Algorithms Over Assumptions
June 26, 2025
The marketing technology sector finds itself at a crossroads that extends far beyond the typical innovation cycle. As adtech companies scramble to incorporate artificial intelligence into their offerings, launching everything from automated creative platforms to machine learning optimization tools, a critical distinction is emerging between organizations that deploy AI strategically versus those that implement it […]
InvestorNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025
June 18, 2025
Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world’s largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
June 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) issued a corporate update emphasizing continued momentum in its clinical pipeline, including the advancement of its lead candidate CYB003 into Phase 3 development. CEO Doug Drysdale underscored the growing regulatory clarity around psychedelic therapeutics and expressed optimism that Cybin’s IP portfolio and clinical strategy position the company to help […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
June 12, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, scheduled for June 16–17, 2025. The company is advancing next-generation neuropsychiatric treatments aimed at transforming mental healthcare. To view the full press release, visit https://ibn.fm/BjhYH About […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives USPTO Notice of Allowance for PTSD Treatment Patent
June 11, 2025
Silo Pharma (NASDAQ: SILO) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its licensed patent application related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders. The patent, set to be issued as U.S. Patent No. 12,329,726 on June 17, 2025, bolsters Silo’s intellectual property around its […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
June 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the Psychedelic Science 2025 Conference, held June 16–20 in Denver. Drysdale will participate in the panel “The Home Stretch: Pivotal Trials and Preparing for Launch” on Thursday, June 19 at 9:30 a.m. MDT. He emphasized the importance of collaborative dialogue in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
June 3, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company focused on next-generation mental health therapies, announced the issuance of U.S. patent 12,318,477 supporting its CYB004 program, a deuterated DMT candidate being developed for generalized anxiety disorder (“GAD”). The patent, which covers novel intramuscular formulations of DMT and related compounds, extends exclusivity through 2040. CEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
May 22, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a Water Tower Research Fireside Chat on May 29, 2025, at 11 a.m. ET. The discussion will cover Cybin’s CYB003 Phase 3 program, recent clinical partnerships, its collaboration with Thermo Fisher, and insights on the evolving regulatory landscape for psychedelics. The event […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with Nasal Spray Device Study for SPC-15
May 21, 2025
Silo Pharma (NASDAQ: SILO) announced a service agreement with Resyca BV to conduct a drug-device study on the microchip-enabled nasal spray system used in its lead PTSD treatment candidate, SPC-15. The study is intended to provide the final device data needed for an Investigational New Drug (IND) application to the FDA later this year. CEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
May 20, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission […]
Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
May 19, 2025
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes $2 Million Public Offering of Shares and Warrants
May 19, 2025
Silo Pharma (NASDAQ: SILO) a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed a public offering totaling approximately $2 million in gross proceeds. The offering included 3,333,338 shares of common stock or pre-funded warrants, along with Series A-1 and Series A-2 warrants, each allowing the purchase of up to 3,333,338 […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
May 16, 2025
Silo Pharma (NASDAQ: SILO) has priced a public offering of approximately 3.33 million shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants, all priced at $0.60 per unit. The Series A-1 and A-2 warrants are immediately exercisable at $0.60 per share, with expirations set at five years and eighteen […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
May 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
May 15, 2025
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
May 14, 2025
Silo Pharma (NASDAQ: SILO) has partnered with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, following a request from the FDA. The intranasal treatment targets PTSD and stress-related disorders, and the study is expected to strengthen Silo’s upcoming IND application. Silo remains on track for an FDA submission […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
May 14, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The session will be webcast live at 1:40 p.m. ET and later available via the company’s investor relations site. To view the full press release, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
May 8, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced the issuance of U.S. patent 12,291,499 for its CYB003 program targeting major depressive disorder (MDD). The patent covers pharmaceutical compositions and oral dosage forms related to Cybin’s proprietary deuterated psilocin analog and offers exclusivity through 2041. The company is currently dosing patients in a Phase […]
NECANN Cannadelic Miami 2025 to Ignite Miami’s Wellness Evolution
May 6, 2025
Researchers, scholars, wellness seekers, and industry experts are invited to attend the NECANN Cannadelic Miami 2025, held at the Miami Airport Convention Center, Miami, FL, from May 23 to 24, 2025. This transformative two-day event empowers attendees to explore the frontiers of emerging therapies, plant-based medicine, and next-gen healing. Based on the inspiring theme “Elevate […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at Milken Global Conference on Medical Breakthroughs
May 1, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the 28th Annual Milken Institute Global Conference on May 5 at 2:30 p.m. PDT. He will join the panel “The Global Landscape and Opportunities for Medical Breakthroughs” to discuss innovation in drug development and next-generation mental health treatments. The event will […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
April 30, 2025
Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fibromyalgia. Conducted in minipigs, the study met all endpoints, including safety, tolerability, and pharmacokinetics, with no implant-related adverse events and sustained ketamine release for up to 22 days. CEO Eric Weisblum said the results support SP-26’s […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
April 28, 2025
Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal compound exclusively licensed from Columbia University targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease. The patent covers SPC-14’s mechanism of action focused on glutamate receptor NDMAR and serotonin 5-HT4, with preclinical studies […]